CD40LG and neoplasm: In the same way, the CD19-CAR T cells genetically engineered to express CD40L, a tumor necrosis factor superfamily member, displayed enhanced antitumor efficacy against CD40+ cancer cells, associated with their ability to affect the tumor phenotype by increasing tumor cell sensitivity to Fas-dependent apoptosis and immune destruction (21).